Corvus Pharmaceuticals (CRVS) Total Liabilities (2022 - 2025)
Historic Total Liabilities for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Q3 2025 value amounting to $8.7 million.
- Corvus Pharmaceuticals' Total Liabilities fell 8123.95% to $8.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.7 million, marking a year-over-year decrease of 8123.95%. This contributed to the annual value of $36.3 million for FY2024, which is 42902.9% up from last year.
- Latest data reveals that Corvus Pharmaceuticals reported Total Liabilities of $8.7 million as of Q3 2025, which was down 8123.95% from $9.2 million recorded in Q2 2025.
- In the past 5 years, Corvus Pharmaceuticals' Total Liabilities registered a high of $46.4 million during Q3 2024, and its lowest value of $6.7 million during Q1 2024.
- Its 4-year average for Total Liabilities is $14.3 million, with a median of $10.1 million in 2025.
- In the last 5 years, Corvus Pharmaceuticals' Total Liabilities surged by 50637.66% in 2024 and then crashed by 8123.95% in 2025.
- Quarter analysis of 4 years shows Corvus Pharmaceuticals' Total Liabilities stood at $12.1 million in 2022, then crashed by 43.35% to $6.9 million in 2023, then skyrocketed by 429.03% to $36.3 million in 2024, then crashed by 76.04% to $8.7 million in 2025.
- Its Total Liabilities was $8.7 million in Q3 2025, compared to $9.2 million in Q2 2025 and $10.1 million in Q1 2025.